TIEA Connectors Raises Rs 77 Crore Series A To Expand EV And Aerospace Component Manufacturing
May 28, 2026
No Comments
- Mon, 1 June 2026
Indian biotech startup Cellogen Therapeutics has raised Rs 20 crore from Kotak Alternate Asset Managers to accelerate its CAR T and gene therapy programs.
The investment was made through Kotak Life Sciences Fund I, which focuses on healthcare and life sciences companies at early and growth stages.
The funding will support the company’s clinical programs, manufacturing capabilities, regulatory expansion, and broader gene therapy pipeline.
CAR T therapies are considered among the most advanced cancer treatments globally, but they remain prohibitively expensive for most patients.
Existing treatments can cost between $500,000 and $700,000 internationally.
Cellogen says it aims to reduce those costs significantly to nearly $60,000 to $70,000, potentially making advanced cancer care more accessible in emerging markets like India.
The startup’s focus reflects a larger shift in India’s biotech ecosystem toward deep science innovation rather than traditional pharmaceutical manufacturing.
Founded in 2021 by Dr. Gaurav Kharya and Dr. Tanveer Ahmad, Cellogen Therapeutics develops cell and gene therapies using CAR T technology.
Its lead program is a bispecific dual antigen CAR T therapy that targets two cancer markers instead of one. The company believes this approach could help reduce relapse risks compared to conventional CAR T therapies.
Beyond cancer treatment, the startup is also working on early stage programs for beta thalassemia and sickle cell disease.
Cellogen is preparing for Phase I human clinical trials in collaboration with Christian Medical College Vellore, subject to regulatory approvals.
The company also operates a GMP compliant manufacturing facility in Noida with in house CAR design and lentiviral vector manufacturing capabilities.
This infrastructure could become a key advantage as India increases investments in biotechnology manufacturing and research capabilities.
India’s biotechnology industry has grown rapidly over the past few years, with more than 11,000 biotech startups now operating across the country.
The recent announcement of the Biopharma SHAKTI scheme in the Union Budget further signals stronger government support for biotech innovation, manufacturing, and research.
For startups like Cellogen, this creates an environment where advanced therapies developed in India could eventually compete on a global scale
contact@GrowthSenseNews.com
Sign up to get exciting updates through our newsletter- your one-stop for all things startup!